Meda Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Solna Sweden (1995)
Status: Acquired by Mylan (2016)

Organization Overview

First Clinical Trial
2018
NCT03599791
First Marketed Drug
1995
carisoprodol (soma)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MEDA Pharma GmbH & Co. KG | Meda Pharma GmbH & Co. KG (A Mylan Company) | MEDA PHARMS